Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07390071 · ClinicalTrials.gov registry record · NA

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

A NA study of Lymphoma and Myeloma, sponsored by University of Utah.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT07390071: Recruiting NA study of Lymphoma and Myeloma, sponsored by University of Utah.

NCT07390071 is a NA study of Lymphoma and Myeloma that is actively recruiting participants, run by University of Utah. The registered enrollment target is 40 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07390071, a NA study of Lymphoma and Myeloma, is actively recruiting participants, sponsored by University of Utah.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The proposed multimodal telerehabilitation model allows a rehabilitation therapy team to set up individualized rehabilitation plans using a web-based care management portal and monitor patient progress online. Patients at home follow a safe and effective personalized exercise and nutrition plan guided by interactive touch-screen technology combined with behavioral counseling, social support, and interactive education and empowerment. The design of the telerehabilitation system is based on the cloud-based Internet-of-Things architecture allowing real-time monitoring of cardiovascular parameters and exercise performance. The patient's level of exertion during exercise is automatically identified by a validated AI-driven algorithm supporting exercise safety and efficacy. The ultimate goal of this pilot feasibility project is to establish the extent of the impact of the proposed patient-centered cancer telerehabilitation model on disease-specific quality of life, and functional and symptom outcomes and to obtain sufficient evidence for a definitive randomized clinical trial evaluating this approach in a multi-center study.

Primary Outcome

To assess the feasibility of a multimodal cancer telerehabilitation model in patients with hematologic malignancies undergoing CAR-T therapy by evaluating system usability, acceptability, and exercise adherence. This outcome measure will report the System Usability Score for home telerehabilitation in patients undergoing CAR-T therapy. The System Usability Scale (SUS) is a 10-item, 5-point Likert questionnaire that yields a single usability score on a 0-100 scale; the minimum possible score is

Interventions

  • DEVICE Home Automated Telemanagement (HAT) Patient Unit

Study Locations (1)

Utah

  • Huntsman Cancer Institute at University of Utah - Salt Lake City

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-09-01
Est. Completion 2029-01
Phase NA
University of Utah

818 total trials

What NCT07390071 shows while recruiting

NCT07390071 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (92% lower).

The record links to 4 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Home Automated Telemanagement (HAT) Patient Unit is the first listed.

NCT07390071 reports a single indexed study location in Utah.

Frequently Asked Questions

What is clinical trial NCT07390071 about?

NCT07390071 is a clinical study titled "Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy". The proposed multimodal telerehabilitation model allows a rehabilitation therapy team to set up individualized rehabilitation plans using a web-based care management portal and monitor patient progress online. Patients at home follow a safe and effective personalized exercise and nutrition plan guid...

What is the current status of trial NCT07390071?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2025-09-01. Estimated completion is 2029-01.

What conditions does trial NCT07390071 study?

This clinical trial studies the following conditions: Lymphoma, Myeloma, Cytokine Release Syndrome, Immune Effector Cell Associated Neurotoxicity Syndrome.

What interventions are being tested in trial NCT07390071?

The interventions under investigation include: Home Automated Telemanagement (HAT) Patient Unit (DEVICE).

Who is sponsoring clinical trial NCT07390071?

This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07390071 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07390071's enrollment target sits among peer trials

40 174th of 299 higher than 116 of 299 other Lymphoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

  • NCT02254863 · 40 participants · Phase 1

    UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07390071, the US trial registry maintained by the National Library of Medicine. NCT07390071 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.